Eli Lilly's next-generation obesity drug makes it nearly impossible to catch

Eli Lilly's experimental drug retatrutide posted late-stage trial results impressive enough that analysts at the American Diabetes Association conference called the company the clear winner of the weight-loss drug race.

That matters because Lilly is not just ahead today; it is building a lead in a market that Wall Street expects to be worth hundreds of billions of dollars, and each new data readout widens the gap rivals like Novo Nordisk will have to close.

Micron's numbers are so strong that last week's selloff looks like a gift

Micron bounced back nearly 10% Monday after last week's sharp drop, as investors refocused on a quarter where revenue tripled year-over-year and the company guided for even bigger numbers ahead.

The rebound also got an unexpected boost from Nvidia's new memory partnership with SK Hynix, a deal some feared would hurt Micron, but the market read it instead as confirmation that AI's appetite for memory chips is large enough for everyone to win.

AstraZeneca's weight-loss pill makes the needle-free option a real competitive threat

AstraZeneca reported Monday that its experimental weight-loss pill, taken by mouth rather than injected, helped patients lose 10.5% of their body weight over six months in a mid-stage trial, a result strong enough to put the company in direct competition with Novo Nordisk and Eli Lilly.

The significance is not just the number but the format: the pill's oral delivery unlocks a patient segment that the current injection-based market leaders have never been able to reach.